(Date:9/5/2008)...on models are enhanced by taking into account risk...ity, according to research teams led by epidemiolo...ncer Center in two complementary papers appearing ...rch . , In the first study to focus on African-A...n increased exposure to certain risks. Based upon ...
(Date:9/4/2008)...wswire/ -- A groundbreaking program,dealing with t...atus of,men, their shorter life spans, unmet gende...ke place Wednesday, September 17 at White Plains,H... of the Westchester,medical and psychiatric societ... and Lionel Tiger, Ph.D., Dr. Legatto, an interna...
(Date:9/4/2008)...ivate Medicare Advantage (MA) plans will be paid a...ompared to what the same enrollee would have cost ...m, according to a new report from The Commonwealth... mandated by the Medicare Improvements for Patient...take effect beginning in 2010 had been fully in p...
(Date:9/4/2008)...ns may be shortchanging their golden years by tapp...University of Illinois expert who has studied the ... , More than three of every four Americans trim ...laiming benefits early, a choice many might forego...nd consequences, law professor Richard L. Kaplan s...
Breaking Medicine News(10 mins):Health News:Creating lung cancer risk models for specific populations refines prediction 2Health News:Creating lung cancer risk models for specific populations refines prediction 3Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3(Date:9/5/2008)... Calif., Sept. 5 /- SARcode...olecule LFA-1 inhibitors,to treat inflammatory dis...SNSS) today announced SARcode,s initiation of a Ph...duct candidate for T-cell mediated ophthalmic,dise...greement providing,SARcode with an exclusive licen...
(Date:9/4/2008)...ept. 4 /- BioForm Medical,...otal clinical study of,Polidocanol, conducted in G...rik KREUSSLER & Co. GmbH (Kreussler), successfully...tted to FDA as part of a New Drug Application,(NDA...the EASI (Efficacy and safety of,Aethoxysklerol co...
(Date:9/4/2008)...Enroll 750 Women at More Than 100 Sites in the U.S...Rx Pharmaceuticals, a,privately-held biopharmaceut...ization of compounds to treat endocrine, metabolic...t it has initiated a second,Phase 3 clinical trial...,estrogen-free oral therapy in development for the...
(Date:9/4/2008)...main on Schedule with Two Abstracts Accepted for ...n November 2008, BRIDGEWATER, N.J., Sept. 4 /PRNe...alty pharmaceutical company focused on the treatme...announced the appointment of,Peter L. Garrambone, ...arrambone,s career includes more than 50 pharmaceu...
Breaking Medicine Technology:SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Marlabs in the Top 10 BPO Healthcare Revenue Cycle Management Companies 474 1Marlabs in the Top 10 BPO Healthcare Revenue Cycle Management Companies 474 2Celebrity Seating Only 21 Levitz Chair Signed by 39 Daytime Stars Sells for 241200 on Charitybuzz com 469 1Celebrity Seating Only 21 Levitz Chair Signed by 39 Daytime Stars Sells for 241200 on Charitybuzz com 469 2BSP Pharma Inc Makers of FlexNow 28TM 29 Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC 339 1BSP Pharma Inc Makers of FlexNow 28TM 29 Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC 339 2No Sheet 3A New Disposable Cover Keeps Bed Bugs at Bay 462 1No Sheet 3A New Disposable Cover Keeps Bed Bugs at Bay 462 2No Sheet 3A New Disposable Cover Keeps Bed Bugs at Bay 462 3...Conn., April 19, 2007 /PRNewswire-FirstCall/ --,Cu...ay that,preliminary interim clinical data on intra...(HDAC) inhibitor being investigated,for the treatm...,upcoming major medical meetings. , One oral and o...,results with belinostat will be made at the 2007 ...
...Mass.--(BUSINESS WIRE)--Apr 18, 2007 - Critical,Th...at new,preclinical research demonstrating a role i... Mobility Group Box-1 protein (HMGB1), a,pro-infla...will be,published in the May 2007 issue of Nature ...1 is part of DNA complexes that,can stimulate immu...
Other Medicine Technology:CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 2CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 3CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 4CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 5Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 2Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 3Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 4Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 5Hudson-Downs Burr
McKenzie Perforator Drill
Cushing Perforator Drill
Self retaining brain retractor.
Medicine Products: